ArticleJournal of translational autoimmunity2026
Aggrecan and polymeric immunoglobulin receptor in extracellular vesicles of patients with seropositive rheumatoid arthritis.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence or absence of autoantibodies distinguishes patients with rheumatoid arthritis (RA) as seropositive (SP) or seronegative (SN), with SP generally associated with poorer prognosis. Extracellular vesicles (EVs) are important mediators of intercellular communication and may contribute to RA pathogenesis by disseminating immunologically active molecules that promote systemic inflammation. However, the protein cargo of circulating EVs associated with RA seropositivity remains poorly characterized. Therefore, we aimed to identify EV-associated proteins linked to RA and seropositivity and evaluate their relationship with clinical features. Methods: Blood-derived EVs were isolated from patients with SP and SN disease and from healthy donors (HD) and were characterized according to international guidelines. EV protein cargo was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differentially enriched proteins were identified in patients, and their associations with serum autoantibody levels, circulating cytokines, and disease activity were assessed. Results: A total of 358 proteins were identified in EVs, most of which have been previously reported in these structures. Several complement proteins, collagens, and immunoglobulins were lower in patients with RA than in HD. Notably, aggrecan (ACAN) and the polymeric immunoglobulin receptor (PIGR), not previously described in RA-derived EVs, were specifically enriched in SP patients compared with both patients with SN RA and HD. Their enrichment was significantly associated with autoantibody levels and disease activity. Conclusion: Our findings identify ACAN and PIGR as novel EV-associated proteins linked to RA seropositivity. Their association with autoantibody levels and disease activity suggests that circulating EVs may reflect biological pathways connecting cartilage remodeling, mucosal immunity, and systemic autoimmunity, supporting their potential utility as biomarkers and contributors to disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.